Abstract
This letter to the editor highlights additional analyses to add to the recently reported study by Rugo et al., regarding abemaciclib treatment for HR+/HER2− breast cancer.
We read with great interest Rugo et al. [1], whose study evaluated the association between early adverse events (AEs) and progression-free survival (PFS) in patients with hormone receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer treated with abemaciclib. However, we highlight two additional analyses that would significantly enhance the completeness of the results reported: (a) impact of dose omissions/interruptions and (b) prognostic association of early AEs by grade of severity.
We read with great interest Rugo et al. [1], whose study evaluated the association between early adverse events (AEs) and progression-free survival (PFS) in patients with hormone receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer treated with abemaciclib. However, we highlight two additional analyses that would significantly enhance the completeness of the results reported: (a) impact of dose omissions/interruptions and (b) prognostic association of early AEs by grade of severity.
| Original language | English |
|---|---|
| Pages (from-to) | e1285 |
| Number of pages | 1 |
| Journal | Oncologist |
| Volume | 26 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2021 |
Keywords
- Abemaciclib
- HR+/HER2− breast cancer
- AE
- Progression-free survival
- Hormone receptor status
- advanced breast cancer
